Novartis Unveils Plans for a New Manufacturing Hub
Novartis, a renowned global leader in innovative medicines, is embarking on an ambitious journey to strengthen its manufacturing presence in the United States. This initiative involves creating a flagship manufacturing hub in North Carolina, which marks a significant investment expected to generate approximately 700 new jobs by the end of 2030.
Strategic Investment in US Infrastructure
This expansion is part of Novartis' broader commitment of $23 billion towards enhancing US infrastructure over the next five years. The goal is simple yet profound: to ensure the seamless production of all key medicines within the US's borders. By establishing this flagship hub, Novartis aims to streamline operations, allowing critical pharmaceuticals to reach patients more efficiently.
End-to-End Manufacturing Capabilities
The North Carolina facility will serve as a centralized site for manufacturing, allowing Novartis to produce medicines across its primary therapeutic areas, including oncology, immunology, neuroscience, and cardiovascular health. By consolidating production facilities, the company enhances operational efficiency, facilitating a smoother workflow from raw ingredient manufacturing to final packaging.
Key Developments in Durham and Morrisville
As part of this expansion, Novartis plans to establish significant new facilities in Durham and Morrisville. In Durham, two new buildings will focus on manufacturing biologics and sterile packaging, while the Morrisville site will be dedicated to producing solid dosage tablets and capsules. Additionally, the existing Durham facility will be upscaled to enhance its capabilities to support sterile filling processes.
Utilizing Advanced Technologies
Novartis is committed to advancing its production capabilities by integrating cutting-edge technologies within these new facilities. The company plans to manufacture cell and gene therapies in both Morris Plains, New Jersey, and Durham, North Carolina. Furthermore, radioligand therapies will be produced across multiple locations, including facilities in Indiana and California, with new sites expected to open in both Florida and Texas.
Commitment to American Patients and Communities
Currently, the company already produces transformative gene therapies in Durham, and these new capabilities will allow Novartis to expand its reach. By building an integrated manufacturing hub, Novartis not only aims to secure a more robust supply chain in the US but also to support local communities and create skilled job opportunities to enhance the local economy.
CEO Vas Narasimhan emphasized the importance of this move by stating, "This announcement demonstrates our dedication to American innovation and the patients we serve. By building a comprehensive manufacturing presence in North Carolina for our extensive portfolio, we expand our capacity to deliver medical breakthroughs, while investing in and empowering the local communities that support our mission."
Community Support and Economic Growth
North Carolina is increasingly recognized as a pivotal location for pharmaceutical advancements. Governor Josh Stein noted that Novartis' expansion reflects the state's talented workforce and innovative spirit. The projected hub, anticipated to cover over 700,000 square feet, is expected to create not only 700 direct jobs at Novartis but potentially over 3,000 indirect jobs within the related supply chain by the year 2030.
Looking Ahead to the Future
With an expected opening date around 2027-2028, this new manufacturing hub signifies a commitment to enhancing public health and ensuring the availability of vital medications for patients across the United States. As Novartis continues to grow its footprint, it reinforces the essential role of pharmaceutical manufacturing in driving local economies and improving lives.
Frequently Asked Questions
What is the significance of Novartis' new manufacturing hub?
The hub will centralize production for key medicines, ensuring faster and more efficient delivery to patients across the United States.
How many jobs will the new facility create?
The expansion is projected to create approximately 700 new jobs at Novartis and over 3,000 jobs indirectly within the supply chain.
When is the new hub expected to open?
The flagship manufacturing hub is anticipated to begin operations around 2027-2028.
What types of medicines will be produced at the new facility?
The hub is designed to manufacture a range of products including biologics, solid dosage forms, and advanced therapies across multiple therapeutic areas.
Who can I contact for more information?
For media inquiries, you can reach out to media.relations@novartis.com and for investor relations, contact investor.relations@novartis.com.
